Biogen Medical Research
Multiple Sclerosis
Scientific Objectives
General Multiple Sclerosis (MS)
The following area of research is currently being considered with a focus on Multiple Sclerosis:
- MS and its treatment in special populations, i.e. geriatric or pediatric patients, family planning, LGBTQ+ patients, underrepresented populations
MS Therapies
Biogen MS therapies include the following products:
- Disease Modifying Therapies
Dimethyl fumarate
Diroximel fumarate
Natalizumab
SC and IM Peginterferon beta-1a
IM Interferon beta-1a
- Symptomatic Therapies
Prolonged-release fampridine (ex-USA)
The following areas of research are currently being considered with a focus on:
- Studies deciphering the neuroprotective potential of dimethyl fumarate
- Studies deciphering how dimethyl fumarate may cause lymphopenia
- Comparative effectiveness as assessed by PROs, quality of life, workability, treatment satisfaction and/or adherence vs newer DMTs in the treatment of naïve and/or switch patients
- Studies deciphering how diroximel fumarate may cause lymphopenia
- Examination of long-term outcomes
- Real world effectiveness, safety and tolerability vs. other platform MS therapies
- Real world comparative effectiveness, switching and sequencing strategies, and adherence to therapies
Out of scope
The following areas of research are not currently being considered for funding:
- Biomarker studies to identify specific responder populations among patients treated with MS therapies
- Studies on MS therapy MoA
Please note that new study proposals originating in Argentina, Australia, Bahrain, Brazil, Bosnia and Hercegovina, Bulgaria, Chile, China, Colombia, Cyprus, Greece, Israel, Japan, Kingdom of Saudi Arabia, Kuwait, Mexico, Montenegro, New Zealand, North Macedonia, Oman, Qatar, Romania, Serbia, United Arab Emirates, and Uruguay are currently not eligible for funding. Investigators from Israel and Greece or Cyprus may reach out to our Partners (Medison and Genesis, respectively) with inquiries for funding.
Research support is awarded on a highly competitive basis, and submission of research proposals in these areas of interest does not guarantee support will be awarded.